Sai Life Sciences’ pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan
Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of Inspection.
Previously, the agency had conducted a three-day long physical audit in the year 2016 and had issued a Certificate of Inspection.
Sai Life Sciences, a leading global Contract Research, Development
& Manufacturing Organization (CRO/ CDMO), today announced that the
Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency
(PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility
in Bidar, India and issued a Certificate of Inspection. Previously, the
agency had conducted a three-day long physical audit in the year 2016
and had issued a Certificate of Inspection.
Making the announcement, Krishna Kanumuri, CEO & Managing Director said, “We are delighted to receive a formal Certificate of Inspection from PMDA, Japan. We have been a reliable supplier of pharmaceutical API to the Japanese market for over five years and this certification is a reaffirmation of our commitment to fulfill the most stringent quality standards of the regulatory agency.”
Sai Life Sciences has a growing presence in the Japanese market. It was the launch site for commercial API supplies of an NCE to Japan and has supplied over 50 tonnes of API over the past five years. It is a supplier of registered starting materials for three commercial APIs. The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product. From a drug discovery perspective, the company has helped several biotech and pharma companies advance programs from HIT to lead optimization / candidate stage, through its chemistry, biology and DMPK services. The company opened its representative office in Tokyo, Japan last year, which serves as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region.
Some of the notable highlights of the Bidar manufacturing facility of Sai Life Sciences:
. 100% track record of successful inspections –
-USFDA (4 times)
- PMDA (twice)
- COFEPRIS, Mexico (once)
. 450KL capacity with 50 production trains
. Containment level of 1µg/m3
. 0.25 – 10 KL reactor sizes
. 21CFR compliant single fluid automation system
. 11 clean rooms of ISO – 8 (Class 100,000)
. Lyophilization at pilot & commercial scale
. Chromatography at commercial scale
. Cryo reactions at 2.5 KL, 4 KL & 5 KL scale
. Highly Potent API facility (Q1-2022)
. Amidites facility (Q1-2022)
. Upcoming facilities
- Dedicated facility for companion animal health products
- Additional 200KL intermediate and API manufacturing capacity
. ISO 14001:2015 and ISO 45001:2018 certified
. Zero liquid discharge facility
. Multiple awards for excellence in energy management and EHS practices.
Sponsored Content How healthcare trends inform dosage formsCapsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op...
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain.
Sponsored Content CPHI Podcast Series: Key Considerations in Selecting the Right CMO PartnerIn this month's episode we hear from Jayna Blake, Senior Project Manager for Technical Programs at Baxter BioPharma Solutions, on key considerations for successful CMO selection.
Sponsored Content PharmaNutra announces new technology to combat iron deficiencyThis oral solution allows for high iron absorption while minimising digestive issues
Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&ASeveral mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...
Sponsored Content Rise in home-based healthcare shaping pharma packaging and drug deliveryThe pharma packaging and drug delivery industry has long been synonymous with rapid innovation. As medicine advances and patient needs change, so too should drug packaging and devices. This has been particularly evident during the pandem...
Sponsored Content Biologics earmarked as opportunity in pharma packaging and drug deliveryThe pharma packaging and drug delivery industry has gone through many evolutions, most notably to meet the challenges posed by the COVID-19 pandemic over the last two years. Disruptions to global supply chains posed a major issue, combined with a sharp...
Sponsored Content Sustainability and digital adoption among trends shaping pharma packaging and drug deliveryThe pharma packaging and drug device industry is constantly evolving to optimise drug delivery, keep up with medical advances and ensure regulatory compliance. Trends like sustainability, cost-efficiency and digitisation continue to shape the sector, a...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance